Navigation Links
Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
Date:4/21/2011

EAST BRUNSWICK, N.J., April 21, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the company will release financial results for the first quarter 2011 prior to the open of the market on Thursday, May 5, 2011.

John H. Johnson, Chief Executive Officer, and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on May 5, 2011, to discuss these results and to answer questions.

To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International). The conference identification number is 61789535. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website fifteen minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on May 5, 2011, through 11:59 p.m. Eastern Time on May 23, 2011, by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number 61789535.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the company website at www.savient.com.

SVNT-I


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
2. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
3. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
4. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
5. Savient Closes Sale of $230 Million in Convertible Senior Notes
6. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
7. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
8. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
9. Savient Pharmaceuticals Announces Search for CEO
10. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
11. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... PUNE, India , May 30, 2016 /PRNewswire/ ... research report "Healthcare Analytical Testing Services Market by ... Monitoring, Bioanalytical Services), by End User (Pharmaceutical Companies, ... published by MarketsandMarkets, The market witnessed healthy growth ... grow at a CAGR of 11.3% between 2016 ...
(Date:5/30/2016)... -- - DCGI grants limited approval to market Stempeucel® ... - Stempeucel® becomes 5th off-the-shelf Stem cell product to be ... - Buerger,s Disease (also known as Thromboangiitis Obliterans) is a major ... - Prevalence of Buerger,s Disease is estimated to be ... persons in the European Community & USA ...
(Date:5/27/2016)... Calif. , May 27, 2016  A new study highlights the necessity of ... by the  Journal of the American College of Radiology , a majority of oncology ... Photo - http://photos.prnewswire.com/prnh/20160527/373022 ... ... Medical Diagnostic Imaging Ampronix ...
Breaking Medicine Technology:
(Date:5/29/2016)... ... 2016 , ... "With 30 unique self-animating web themed intros and complete control ... project," said Christina Austin - CEO of Pixel Film Studios. , ProIntro Web ... in Final Cut Pro X. Pixel Film Studios’ minimalistic titles allow users to add ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the ... extraordinary event. The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 ... and the United Kingdom came together to explore the many pathways individuals use to get ...
(Date:5/27/2016)... ... 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield of ... 2016 honorees. The award recognizes businesswomen who excel in their fields and who ... the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and Theresa ...
(Date:5/27/2016)... ... ... This campaign aims to provide a path to improved education and awareness ... change. , As nearly 795,000 Americans suffering from a new or recurrent stoke each ... an estimated 129,000 of these people dying from stroke, it’s become our nation’s fifth-leading ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses ... human interest stories, courtesy of leaders in the nursing and health care industry. ... from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett ...
Breaking Medicine News(10 mins):